Chongqing Genrix Biopharmaceutical News

Zhixiang Jintai-U (688443): Celiac's sales exceeded expectations, commercialization results are beginning to show

gtjaNov 3 00:00

Zhixiang Jintai (688443): Celiac monoclonal was approved for marketing, and the core product is progressing smoothly

Sep 9 20:41

Zhixiang Jintai (688443): IL-17 starts commercialization and the research pipeline is progressing steadily

Sep 2 07:51

Zhixiang Jintai (688443): Self-free layout of a multi-dimensional dual-antibody platform gradually materialized

Aug 8 00:00

Zhixiang Jintai (688443) 2024EHA BCMAXCD3 dual antibody data review: IL17 with excellent BCMA dual antibody data is about to be approved

May 15 15:42

Zhixiang Jintai (688443): Major milestones have been made in various products

May 13 14:31

Zhixiang Jintai (688443): Advancing the research pipeline in an orderly manner, Celiac monoclonal antibody is about to be approved

May 5 19:31

Zhixiang Jintai (688443): Celizumab approved soon, multiple assets are in the advanced clinical phase

May 1 13:31

Zhixiang Jintai (688443): GR1501 is about to be approved, and the pipeline has sufficient reserve capacity

Apr 30 09:41

Zhixiang Jintai (688443): IL-17A monoclonal antibody is being approved and is progressing rapidly in the development pipeline

Apr 30 00:00

Open Source Securities released a research report on April 17 stating that it gave Zhixiang Jintai (688443.SH) a purchase rating. The main reasons for the rating include: 1) Zhixiang Jintai: focusing on antibody drug technology research and development, d

Zhitong FinanceApr 18 14:21

Zhixiang Jintai (688443) Company's first coverage report: Focusing on antibody drug development, the single product IL-17A monoclonal antibody is expected to be approved soon

Apr 17 00:00

Zhixiang Jintai (688443): The commercialization of GR1501 is imminent, and the research pipeline is progressing positively

Feb 28 18:26

Zhixiang Jintai-U (688443) 2023 performance report review: GR1501 is poised to launch multiple pipelines to enter key clinical trials

Feb 26 18:41

Zhixiang Jintai (688443): GR1501 is poised to launch multiple pipelines to enter critical clinical trials

Feb 26 08:36

Zhixiang Jintai (688443): Comprehensive development of monoclonal and dual antibody drugs to establish a leading position in self-immunity and infectious diseases

Feb 22 18:51

Zhixiang Jintai (688443): Leading the progress of domestic IL-17A with extensive layout in the fields of immunity, infection and oncology

Feb 20 18:36

Zhixiang Jintai (688443): Free from the circuit, competes for the rising domestic star Peng, soars on the road

Feb 7 16:51

Zhixiang Jintai (688443): Self-exempt new drugs are about to be approved, double resistance opens the blue ocean market

Nov 23, 2023 07:22

Zhixiang Jintai-U (688443): Increased investment in R&D, celiac monoclonal antibody is about to be approved

Nov 13, 2023 07:42